Physician profile
Thuy Bich Le
NPI 1851356828
$23,504.80
in general payments reported to CMS, 2019-2025
72 companies · $3,877 in 2025
The $3,877 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $354 · 2021: $2,423 · 2022: $2,188 · 2023: $5,219 · 2024: $8,990 · 2025: $3,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $4,940 · Travel and Lodging: $1,183 · Education: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,211.51 |
| Consulting Fee | $4,940.00 |
| Travel and Lodging | $1,182.88 |
| Education | $750.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,272.42 | 2023-2025 | Rybrevant, Darzalex, Tecvayli |
| Emd Serono, INC. | $2,364.86 | 2021-2025 | Bavencio, Tepmetko |
| Gilead Sciences, INC. | $2,149.93 | 2019-2025 | Trodelvy |
| Baxter Healthcare | $1,395.23 | 2024 | |
| Novartis Pharmaceuticals Corporation | $1,060.54 | 2019-2025 | |
| Daiichi Sankyo INC. | $842.19 | 2019-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $777.16 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Scientific Affairs, LLC | $757.50 | 2022 | |
| Pfizer INC. | $729.89 | 2022-2025 | |
| Astellas Pharma US INC | $643.18 | 2020-2025 | Cresemba, Padcev, Xospata |
| Incyte Corporation | $610.03 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $558.12 | 2020-2025 | Enhertu, Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $482.73 | 2019-2025 | Opdivo |
| Seagen INC. | $479.40 | 2019-2025 | Tukysa, Padcev, Adcetris |
| Genzyme Corporation | $337.46 | 2020-2025 |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $327.47 | 2022-2025 | Fruzaqla, Iclusig, Alunbrig |
| Abbvie INC. | $306.36 | 2021-2025 | |
| Eisai INC. | $258.77 | 2022-2025 | |
| Sobi, INC | $256.28 | 2022-2025 | |
| Array Biopharma INC | $255.87 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Glaxosmithkline, LLC. | $251.54 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Jazz Pharmaceuticals INC. | $250.91 | 2023-2025 | Zepzelca |
| Pharmaessentia USA Corporation | $222.89 | 2023-2025 | Besremi |
| Puma Biotechnology, INC. | $213.17 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $207.59 | 2023-2025 | |
| Genentech USA, INC. | $190.81 | 2019-2024 | Phesgo, Tecentriq, Polivy |
| Epizyme, INC. | $185.79 | 2022 | |
| Kite Pharma, INC. | $175.17 | 2021-2024 | Yescarta |
| Sirtex Medical INC | $170.78 | 2023-2025 | Sir-Spheres Microspheres |
| Adaptive Biotechnologies Corporation | $170.39 | 2023-2025 | Clonoseq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.86 | 2023-2025 | Gilotrif |
| Aveo Pharmaceuticals, INC. | $154.79 | 2021-2025 | Fotivda |
| Kyowa Kirin, INC. | $145.15 | 2019-2025 | Poteligeo |
| Lilly USA, LLC | $139.37 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Stemline Therapeutics INC. | $124.61 | 2023-2025 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $117.42 | 2022-2023 | Imbruvica, Epkinly |
| Rigel Pharmaceuticals, INC. | $111.91 | 2021-2024 | Tavalisse, Rezlidhia |
| Celgene Corporation | $107.61 | 2020-2025 | Pomalyst, Reblozyl |
| Exelixis INC. | $105.47 | 2022-2025 | Cabometyx |
| Apellis Pharmaceuticals, INC. | $96.05 | 2022-2025 | Empaveli |
| Regeneron Healthcare Solutions, INC. | $91.25 | 2021-2025 | Libtayo, Lynozyfic |
| Beone Medicines USA, INC. | $84.92 | 2025 | Brukinsa, Tevimbra |
| Legend Biotech USA INC. | $83.36 | 2025 | Carvykti |
| Karyopharm Therapeutics INC. | $79.70 | 2021-2025 | Xpovio |
| Cti Biopharma Corp. | $68.91 | 2023 | Vonjo |
| Adc Therapeutics America, INC. | $66.26 | 2024-2025 | |
| Mirati Therapeutics, INC. | $64.40 | 2023-2024 | Krazati |
| Amgen INC. | $63.47 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Myriad Genetic Laboratories, INC. | $62.54 | 2021-2022 | |
| Geron Corporation | $49.14 | 2025 | Rytelo |
| Acrotech Biopharma INC. | $46.75 | 2022-2023 | Beleodaq |
| Ipsen Biopharmaceuticals, INC | $45.63 | 2023 | Onivyde, Somatuline Depot |
| Agios Pharmaceuticals, INC. | $44.45 | 2025 | Pyrukynd |
| Blueprint Medicines Corporation | $42.87 | 2020-2023 | Ayvakit |
| Servier Pharmaceuticals LLC | $42.02 | 2024 | |
| Taiho Oncology, INC. | $41.11 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $35.99 | 2025 | |
| Immunocore Limited | $34.37 | 2023-2024 | Kimmtrak |
| Dendreon Pharmaceuticals LLC | $31.35 | 2024 | Provenge |
| Genmab U.S., INC. | $26.97 | 2023-2024 | Epkinly |
| Ge Healthcare | $26.74 | 2022 | |
| Napo Pharmaceuticals INC | $23.71 | 2024 | Gelclair Concentrated Oral Gel |
| Sun Pharmaceutical Industries INC. | $23.53 | 2025 | |
| Beigene USA, INC. | $23.17 | 2023 | Brukinsa |
| Masimo Corporation | $20.33 | 2022 | |
| Foundation Medicine, INC. | $19.21 | 2023 | |
| Iovance Biotherapeutics, INC. | $19.13 | 2025 | Amtagvi |
| Recordati_rare_diseases_inc. | $18.31 | 2023 | Sylvant |
| Menarini Silicon Biosystems, INC. | $16.67 | 2023 | Cellsearch |
| Springworks Therapeutics, INC. | $14.67 | 2024 | Ogsiveo |
| Cumberland Pharmaceuticals, INC. | $14.24 | 2024 | Sancuso |
| Janssen Pharmaceuticals, INC | $6.96 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuy Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.